Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Apr:71:152649.
doi: 10.1016/j.semarthrit.2025.152649. Epub 2025 Feb 1.

Psychometric properties of patient-reported outcomes measurement information system (PROMIS) fixed short forms in Juvenile Myositis

Kaveh Ardalan  1 , Mariana C Marques  2 , David Cella  3 , Megan L Curran  4 , Elizabeth L Gray  5 , Jungwha Lee  5 , Kyle J Fahey  6 , Madison L Wolfe  7 , Lauren M Pachman  8 , Rowland W Chang  9
Affiliations

Psychometric properties of patient-reported outcomes measurement information system (PROMIS) fixed short forms in Juvenile Myositis

Kaveh Ardalan et al. Semin Arthritis Rheum. 2025 Apr.

Abstract

Objectives: Assess reliability and validity of Patient-Reported Outcomes Measurement Information System (PROMIS) pediatric self-report and parent-proxy report fixed short forms in juvenile myositis (JM).

Methods: Children with JM (8-17yo) and parents of 5-17 yo JM patients completed PROMIS measures (Physical Function, Pain Interference, Fatigue, Emotional Distress), PedsQL Generic Core scales and Rheumatology Module (PedsQL-GC/-RM). Internal consistency reliability was assessed via Cronbach's alpha. Patient-parent agreement was assessed via intraclass correlations (ICC). Concurrent and construct validity were assessed via Spearman's correlations between PROMIS versus PedsQL-GC/-RM and clinical/lab data respectively. Known-groups validity was assessed by comparing PROMIS T-scores between clinically distinct JM patients.

Results: We enrolled 75 JM participants, with 57 administered self-report and all 75 administered parent-proxy report measures per participant age. PROMIS measures were feasible (>96% completion), with high internal consistency reliability (Cronbach's alpha >0.8). Patient-parent assessments demonstrated moderate agreement (ICC >0.5) for Mobility, Upper Extremity, and Fatigue domains, and smaller correlations (ICC 0.41-0.47) as expected for Pain Interference, Depressive Symptoms, and Anxiety. Concurrent validity was demonstrated by moderate correlation (Spearman's rho >0.5) for all but 1 hypothesized relationships of PROMIS and PedsQL-GC/-RM domains. Although low disease activity and small sample size limited statistical power, construct validity and known-groups validity were demonstrable for multiple PROMIS pediatric self-report and parent-proxy report measures.

Conclusion: PROMIS measures show evidence of reliability and validity in JM. Child and parent reports differ sufficiently to suggest both should be collected. PROMIS measures can be considered for clinical and research use in JM.

Keywords: Juvenile dermatomyositis; Juvenile myositis; Patient-reported outcomes; Psychometrics; Quality of life.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Kaveh Ardalan reports consulting fees and service on a scientific advisory board for Cabaletta Bio and funding from Cure JM Foundation to assist ReveraGen BioPharma with clinical trial design (but no funds received directly from ReveraGen BioPharma). Mariana C. Marques reports receiving a monetary award from the Rheumatology Research Foundation in 2022 for Pediatric Rheumatology Research Award. David Cella reports being a board member of the PROMIS Health Organization. The remaining authors did not report any relevant conflicts of interest.

References

    1. Rider LG and Nistala K, “The juvenile idiopathic inflammatory myopathies: pathogenesis, clinical and autoantibody phenotypes, and outcomes,” J. Intern. Med, vol. 280, no. 1, pp. 24–38, Jul. 2016, doi: 10.1111/joim.12444. - DOI - PMC - PubMed
    1. Neely J, Ardalan K, Huber A, Kim S, and for the Childhood Arthritis and Rheumatology Research Alliance Investigators, “Baseline characteristics of children with juvenile dermatomyositis enrolled in the first year of the new Childhood Arthritis and Rheumatology Research Alliance registry,” Pediatr. Rheumatol, vol. 20, no. 1, p. 50, Jul. 2022, doi: 10.1186/s12969-022-00709-3. - DOI - PMC - PubMed
    1. Apaz MT et al., “Health-related quality of life of patients with juvenile dermatomyositis: Results from the Paediatric Rheumatology International Trials Organisation multinational quality of life cohort study,” Arthritis Rheum, vol. 61, no. 4, pp. 509–517, Apr. 2009, doi: 10.1002/art.24343. - DOI - PubMed
    1. Ardalan K et al., “Parent perspectives on addressing emotional health for children and young adults with juvenile myositis,” Arthritis Care Res, vol. 73, no. 1, pp. 18–29, Jan. 2021, doi: 10.1002/acr.24466. - DOI - PMC - PubMed
    1. Kountz-Edwards S, Aoki C, Gannon C, Gomez R, Cordova M, and Packman W, “The family impact of caring for a child with juvenile dermatomyositis,” Chronic Illn, vol. 13, no. 4, pp. 262–274, Dec. 2017, doi: 10.1177/1742395317690034. - DOI - PubMed

Publication types

LinkOut - more resources